Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy

Shingo Toyoda; Wataru Fukuokaya; Keiichiro Mori; Tatsushi Kawada; Satoshi Katayama; Shingo Nishimura; Ryoichi Maenosono; Takuya Tsujino; Takahiro Adachi; Yosuke Hirasawa; Masanobu Saruta; Kazumasa Komura; Takuhisa Nukaya; Takafumi Yanagisawa; Kiyoshi Takahara; Takeshi Hashimoto; Haruhito Azuma; Yoshio Ohno; Ryoichi Shiroki; Motoo Araki; Takahiro Kimura; Kazutoshi Fujita

doi:10.1093/jjco/hyae108

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Metastatic nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous disease with poor prognosis. The clinical characteristics and prognostic factors of immuno-oncology (IO) combination therapy for nccRCC are not well known. This study analyzed patients with metastatic nccRCC treated with IO combination therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Toyoda et al. (2024) studied this question.

synapsesocial.com/papers/68e5b3bab6db64358754cdad https://doi.org/10.1093/jjco/hyae108

View at Publisher

Ask AI

Bookmark

Share

Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy

Ask about this paper

Abstract

Discussion

Cite This Study

Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading